The Pharmaceuticals Division of Novartis is recognized worldwide for the innovative products, services and solutions we provide to patients, physicians and healthcare organizations. This growing business works to change the way medicine is practiced by following the science to deliver the right treatment to the right patient at the right time.
The Pharmaceuticals Division researches, develops, manufactures, distributes and sells branded pharmaceuticals used to treat diseases and conditions across a variety of therapeutic areas, including: auto-immunity, cardiovascular, dermatology, infectious diseases, metabolism, neuroscience, oncology, ophthalmology, respiratory, rheumatology, and transplantation.
The Division is organized into global business franchises and an Oncology business unit responsible for the commercialization of various products:
Cell and Gene Therapies
The current product portfolio includes more than 50 key marketed products, many of which are leaders in their respective therapeutic areas. In 2013 we received a total of 13 approvals in the United States, Europe and Japan.
In 2013 Novartis received three US FDA Breakthrough Therapy designations: LDK378 in lung cancer, RLX030 (serelaxin) in acute heart failure and BYM338 (bimagrumab) in sporadic inclusion body myositis.
The product development pipeline has 144 projects in various stages of clinical development, including potential new products as well as potential new indications or formulations for existing products.